Navigation Links
MonoSol Rx Appoints Theodore Clemente Vice President Business Development
Date:7/23/2009

WARREN, N.J., July 23 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm((R)) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced the appointment of Theodore "Ted" Clemente, Jr. as Vice President, Business Development. Mr. Clemente will report to Keith J. Kendall, Executive Vice President and CFO.

Mr. Kendall stated, "We are pleased to welcome Ted to MonoSol Rx and look forward to benefiting from his expertise as we continue to identify and secure opportunities that leverage the unique attributes of our PharmFilm((R)) technology. Through our strategic partnerships and recent NDA submission for ondansetron orally dissolving thin film, we have validated our thin film platform and its potential to develop new, highly differentiated drug compounds that offer improved compliance, convenience and efficacy. Ted's knowledge of the pharmaceutical industry, and in particular the pressures that companies now face in trying to account for generic encroachment and pending exclusivity losses, will be instrumental as we extend our development pipeline and target additional partnership arrangements."

Prior to joining MonoSol Rx, Mr. Clemente spent the past 12 years with Novartis Consumer Health, Inc. where he most recently served as the Company's Director, Global Business Development and Licensing. While at Novartis Consumer Health, Mr. Clemente built an extensive track record identifying, negotiating and licensing a variety of drug and technology platforms. Among his numerous accomplishments, Mr. Clemente successfully led negotiations for Novartis Consumer Health to acquire exclusive U.S. rights for over-the-counter Prevacid and was responsible for closing the Company's licensing and supply agreement for Triaminic.

A 30-year veteran of the pharmaceutical industry, Mr. Clemente has also held product development and managerial positions with Ciba Self-Medication, Inc., Hoechst-Roussell Pharmaceuticals and Bristol-Myers Products. Mr. Clemente is a graduate of Rutgers College of Pharmacy, Rutgers University.

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver drugs in quick dissolving films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in thin film drug delivery is supported by strong intellectual property, a portfolio of commercialized over-the-counter (OTC) drug products, and a development pipeline of prescription formulations based on PharmFilm(R) technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that fund prescription product development programs that will generate long-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing. For existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).

    The Ruth Group                        Contact:
    Jason Rando (media)                   MonoSol Rx
    (646) 536-7025                        Keith Kendall
    jrando@theruthgroup.com               Chief Financial Officer
    Sara Ephraim Pellegrino (investors)   (732) 564-5000
    (646) 536-7002
    sephraim@theruthgroup.com


'/>"/>
SOURCE MonoSol Rx
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
2. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
3. MonoSol Rx Granted U.S. Article of Manufacture Patent
4. MonoSol Rx Enters Agreement with Hikma Pharmaceuticals PLC for Thin Film Pharmaceutical Products in the Middle East
5. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
6. MonoSol Rx to Present at the 20th Annual Piper Jaffray Health Care Conference
7. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
8. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
9. MonoSol Rx Names Vincent Viviani Senior Vice President, Manufacturing and Operations
10. MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
11. WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: